marcoola

marcoola
Send Message
View as an RSS Feed
  • Did Investors Overreact To Approach Resources' Earnings?  [View article]
    "Approach Resources is currently working to expand land ownership .."
    I am not so sure about that statement. An Australian registered company Molopo Energy had 20,000 net acres neighbouring Approach's acreage and after disappointing drill results tried to sell the acreage but couldn't and have let most of that acreage lapse and expire.
    BHP have also sold or at least trying to sell their acreage in Crockett County.
    Maybe the focus is now on improving well performance rather than aggregating acreage.
    Aug 14, 2014. 07:51 PM | Likes Like |Link to Comment
  • Dendreon sale makes sense: Credit Suisse  [View news story]
    Does the sale of Dendreon make sense?

    Of course, its the only thing that makes sense.
    Unfortunately former shareholders like myself knew that selling was the only viable alternative 12 months ago.
    Why the company had to wait until the sp was decimated before coming to the same conclusion, only they might know.
    Oct 27, 2013. 08:37 PM | 4 Likes Like |Link to Comment
  • Dendreon Gets European Recommendation  [View article]
    "On the up side, having been approved in the U.S. and Europe it should be possible to gain approvals in many other nations without further clinical trials."

    Approval is one thing. Sales is another.
    I can only see this as a upside, if they find a way to make the patients provenge in the US and deliver it from there.
    Japan might be the exception
    Jun 28, 2013. 04:42 PM | Likes Like |Link to Comment
  • Wedbush analyst David Nierengarten says Dendreon's (DNDN +4.2%) chances with Provenge in the EU are practically zero. While the EMA is likely to grant approval, Nierengarten asks "Who's going to make it?" He points out that no European manufacturer has yet stepped up to work with the company. "All-in," he concludes, "we do not estimate any sales for Provenge in the EU, and we do not believe the European opportunity, if there is one, would be profitable in any significance."  [View news story]
    The concern I have, is that there has been no sign of any progress towards a partnership in Europe.
    Surely, it would have been locked in by now, if they could actually find a willing partner.
    There would be enormous upfront facility costs for someone to bear and the future of Provenge in the US is still not clear after 3 years.
    Would be a brave partner to take this on.
    Jun 28, 2013. 04:36 PM | Likes Like |Link to Comment
  • Is It Time To Give Up On Dendreon?  [View article]
    ".they have more than enough cash to hit breakeven."
    They would say that wouldn't they.
    And supposing that they do, they will still need more money in the bank to be a sustainable operation..
    It's crazy that they are taking on all the general and administration expenses of running a public company while relying on the sales of 1 drug.
    They need to be seeking for a buy out or at least partners.
    May 12, 2013. 12:31 AM | Likes Like |Link to Comment
  • Is It Time To Give Up On Dendreon?  [View article]
    will that be enough to stop the sp falling below $4?
    And hard to feel they can turn this around before they run out of money.
    May 9, 2013. 09:21 AM | Likes Like |Link to Comment
  • Is It Time To Give Up On Dendreon?  [View article]
    Net product revenue for the quarter was $67.6 million compared to $82.0 million for the quarter ended March 31, 2012, down 17.6% year over year.
    337 million left in kitty.:(
    May 9, 2013. 08:47 AM | Likes Like |Link to Comment
  • Bracing For Dendreon Q1 2013 Earnings - All Eyes On Provenge  [View article]
    Net product revenue for the quarter was $67.6 million compared to $82.0 million for the quarter ended March 31, 2012, down 17.6% year over year.
    I could cry
    May 9, 2013. 08:41 AM | Likes Like |Link to Comment
  • Is It Time To Give Up On Dendreon?  [View article]
    We'll have a better idea on whether to give up on Dendreon in a couple of days when they announce their first quarter results
    Analysts are looking for " revenue to decrease 2.3% year-over-year to $80.2 million for the quarter, after being $82.1 million a year ago."

    This seems to me to be highly optimistic, when accounting for the companies guidance that this quarter revenue will be "meaningful lower"
    May 8, 2013. 03:28 AM | Likes Like |Link to Comment
  • Dendreon's Provenge Ads: Are They Working?  [View article]
    This is the transcript from the Cowen and Company Healthcare Conference March 5 by Greg Schiffman

    "After our calls we look at the updated analyst consensus for Q1, it’s approximately $80.6 million or about $1 million down from our Q4 pro forma revenue. To be premature as we indicated in the call for us give any specific estimate of Q1 revenue at this point in time, so we indicated on our call, there are variety of factors, which could dramatically impact the range of decline.

    However, I would note that $1 million reduction from Q4 is within range of error that’s outside of our forecast accuracy, would represent an error rate that would not have caused us to announce reduced expectations for Q1.

    We think that sales maybe meaningfully below Q4. However as we indicate on the call, there is a lot of causes that are temporary and other causes that are being counteracted by positive trends."

    I take "meaningfully lower Q4' as company speak for it's going to be a shocker.
    The other thing that worries me, is that Dendreon have been saying for a long time, since Mitch Gold's time, that they expect to be cash flow positive with $400 million yearly sales.
    Yet the company is making new guidance about cutting its cgs to less than 50%.
    Wouldn't that lower it's require revenue to be cash flow positive?

    Also Dendreon have done DTC ads before in 2011 in newspapers
    Apr 3, 2013. 05:02 PM | Likes Like |Link to Comment
  • Dendreon's Provenge Ads: Are They Working?  [View article]
    Thanks Ted.
    It's great that interest in provenge has picked up, but that it is only to the levels of 12 months ago, is a worry.
    Revenue has been static for over 12 months now and for 1Q13 ,the company has warned revenue will be considerably lower than recent quarters,which is more alarming than the "...it did not expect 1Q13 revenues to exceed those of 4Q12." as you wrote.

    Let's hope there is a surprise to the upside or else those May 2013 $3 PUTs might just be in the money.
    Cheers,
    Alan
    Apr 3, 2013. 02:10 PM | Likes Like |Link to Comment
  • Dendreon's Management Presents at 25th Annual ROTH Conference (Transcript)  [View article]
    For all the companies talk about growth, the fact is that product sales of Provenge have been stagnant now for 5 quarterly periods, and this present period is forecast to be lower than all of those.
    Revenue is going backwards and if feedback from doctors and patients were so positive then word of mouth would be sufficient and DTC ads would not be needed.
    You can fool some of the people some of the time....
    Mar 18, 2013. 08:20 PM | Likes Like |Link to Comment
  • Dendreon: Time Is Not On Your Side  [View article]
    Thank you for a clear analysis of Dendreon's financial situation.
    The prospect of a $100 million quarter seems further away than ever with the company forecasting a significant drop in this quarters revenue.
    The company hasn't been able to convince the doctors of Provenge's merits so now is hoping to convince the public.
    Us shareholders are hoping the Europeans authorities will be.
    Mar 15, 2013. 05:40 AM | Likes Like |Link to Comment
  • 2013 GU: Dendreon's Neuvenge, A First Look At The Clinical Trial Results  [View article]
    Thanks for another insightful article on Dendreon Mr.Cohen.
    I'd like to be excited about Nuevenge , but it's hard to, when you realise even if the treatment gets all the way to approval, the company may still struggle to profit from it.
    That is, if it comes with the same costs of provenge.
    :(
    Feb 15, 2013. 12:42 PM | Likes Like |Link to Comment
  • A Comprehensive Look At Immunotherapy With Analyst/Immunologist Dr. Rahul Jasuja  [View article]
    I thought the article was enlightening.
    Thankyou.
    Feb 8, 2013. 02:07 PM | Likes Like |Link to Comment
COMMENTS STATS
21 Comments
6 Likes